Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
biochemistry, genetics and molecular biology
Therapeutic Monoclonal Antibodies for Ebola Virus Infection Derived from Vaccinated Humans
Cell Reports, Volume 27, No. 1, Year 2019
Notification
URL copied to clipboard!
Description
We describe therapeutic monoclonal antibodies isolated from human volunteers vaccinated with recombinant adenovirus expressing Ebola virus glycoprotein (EBOV GP) and boosted with modified vaccinia virus Ankara. Among 82 antibodies isolated from peripheral blood B cells, almost half neutralized GP pseudotyped influenza virus. The antibody response was diverse in gene usage and epitope recognition. Although close to germline in sequence, neutralizing antibodies with binding affinities in the nano- to pico-molar range, similar to “affinity matured” antibodies from convalescent donors, were found. They recognized the mucin-like domain, glycan cap, receptor binding region, and the base of the glycoprotein. A cross-reactive cocktail of four antibodies, targeting the latter three non-overlapping epitopes, given on day 3 of EBOV infection, completely protected guinea pigs. This study highlights the value of experimental vaccine trials as a rich source of therapeutic human monoclonal antibodies. Most antibodies used for Ebola virus treatment originate from convalescent donors or highly immunized animals. Rijal et al. find that monoclonal antibodies isolated early after vaccination from humans can be powerfully therapeutic, despite the relative immaturity of their sequences. Vaccine trials therefore can provide a valuable source of therapeutic antibodies. © 2019 The Authors
Authors & Co-Authors
Rijal, Pramila
United Kingdom, Oxford
Mrc Weatherall Institute of Molecular Medicine
Elias, Sean C.
United Kingdom, Oxford
The Jenner Institute
Schimanski, Lisa M.
United Kingdom, Oxford
Mrc Weatherall Institute of Molecular Medicine
Jin, Jing
United Kingdom, Oxford
The Jenner Institute
Labbé, Geneviève M.C.
United Kingdom, Oxford
The Jenner Institute
Rampling, Tommy W.
United Kingdom, Oxford
The Jenner Institute
Dowall, Stuart David
United Kingdom, London
Public Health England
Rayner, Emma L.
United Kingdom, London
Public Health England
Findlay-Wilson, Stephen J.D.
United Kingdom, London
Public Health England
Carroll, Miles W.
United Kingdom, London
Public Health England
Huang, Kuan Ying Arthur
Taiwan, Taipei
Chang Gung Memorial Hospital
Takada, Ayato
Japan, Sapporo
Hokkaido University
Draper, Simon J.
United Kingdom, Oxford
The Jenner Institute
Townsend, Alain R.M.
United Kingdom, Oxford
Mrc Weatherall Institute of Molecular Medicine
Statistics
Citations: 52
Authors: 14
Affiliations: 7
Identifiers
Doi:
10.1016/j.celrep.2019.03.020
ISSN:
22111247
Research Areas
Genetics And Genomics
Infectious Diseases
Study Locations
Guinea